Journey Medical (DERM) Q2 FY26 earnings call

Journey Medical delivered strong Q2 FY26 results, driven by accelerating growth in Emrosi prescriptions, an expanding prescriber base, and improving payer access. The company achieved positive non-GAAP EBITDA and strategically expanded its commercial team, positioning for continued revenue growth and profitability. Management reiterated its belief that 2026 will be a breakout year for the company.